Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein

Abstract In this study, a novel theranostic radiopharmaceutical, [13xLa]La-FAP-2286, for targeting Fibroblast Activation Protein (FAP)-positive tumors. The theranostic pair of 132La (half-life: 4.59 h, 42.1% β⁺) and 135La (half-life: 18.91 h, 100% EC) was produced via proton bombardment of natural b...

Full description

Saved in:
Bibliographic Details
Main Authors: Ali Shirpour, Asghar Hadadi, Samaneh Zolghadri, Sara Vosoughi, Saeed Rajabifar
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-91716-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items